Clinical Trials Browser

Phase 2/3 × ZYC101a × Clear all

NCT00264732 2013-05-29

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

Phase 2/3 Completed

Uterine Cervical Dysplasia